Background In the ZUMA-5 trial (Clinical trials identification: NCT03105336), axicabtagene
ciloleucel (axi-cel; a chimeric antigen receptor T-cell therapy) demonstrated high rates of …

The ELARA trial indicates tisagenlecleucel (tisa-cel) is an effective anti-CD19 chimeric
antigen receptor T-cell therapy for relapsed or refractory follicular lymphoma (r/r FL). As …

Indolent B-cell non-Hodgkin lymphomas (B-NHL), chronic lymphocytic leukemia (CLL), and
mantle cell lymphoma (MCL) are widely treatable but typically incurable with conventional …

The SCHOLAR-5 study examines treatment patterns and outcomes of real-world follicular
lymphoma (FL) patients on 3 rd line of treatment (LoT) or higher, for whom existing data are …

The phase 3 SELENE study evaluated ibrutinib+ chemoimmunotherapy (CIT; bendamustine
and rituximab [BR]; or rituximab, cyclophosphamide, doxorubicin, vincristine, and …

Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL)
in the third-or later-line setting. The primary analysis (median follow-up, 17 months) of the …

Mosunetuzumab is a novel bispecific antibody targeting epitopes on CD3 on T cells and
CD20 on B cells with the goal of inducing T-cell mediated elimination of malignant B cells. A …

Background A standard of care and optimal duration of therapy have not been established
for patients with multiply relapsed or refractory follicular lymphoma. The aim of this study was …

Background Follicular lymphoma (FL) is characterized by an incurable course that frequently
necessitates multiple lines of treatment. While a range of new approaches have broadened …

The future directions in leveraging real-world evidence (RWE) and real-world data (RWD) in
the field of lymphoma, as compared to traditional experimental clinical trials, are poised to …